

USSN: 10/057,467

ATTY. DOCKET NO: RIGL-00500N



AMENDMENTS TO THE SPECIFICATION

Please delete the paragraph of line 7 of page 1. This paragraph starts with "Inventors: Garry P. Nolan.....".

Please delete the paragraph of line 8 of page 1. This paragraph starts with "Attorney: Richard Aron.....".

Please amend the paragraph starting on line 14 of page 7 as follows:

A wide variety of cells may be used depending on the nature of the targeted cellular pathway, so long as the cells is suitably transfectable with the library and may be monitored for the targeted physiological changes. The method of introduction is largely dictated by the targeted cell type. Exemplary methods include CaPO₄ precipitation, liposome fusion, lipofectin® using LIPOFECTINT™ phospholipids, electroporation, viral infection, etc. As many pharmaceutically important screens require human or model mammalian cell targets, retroviral vectors capable of transfecting such targets are frequently employed. A particularly well-suited retroviral transfection system is described in Mann et al.(1983) Cell 33, 153-159, Pear et al. (1993) Proc. Natl. Acad. Sci. USA 90(18):8392-6 and copending US patent application Serial No. 08/023,909.